Matinas BioPharma Holdings (MTNB) Cash & Current Investments (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Cash & Current Investments of $2.4 million for Q1 2026, down 64.9% year-over-year from $7.0 million in Q1 2025, and down 39.54% quarter-over-quarter from $4.0 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Cash & Current Investments (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Cash & Current Investments for 14 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 64.9% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 64.9% YoY), while the FY2025 annual figure was $4.0 million, down 44.79% from the prior year.
- Cash & Current Investments eased to $2.4 million in Q1 2026 per MTNB's latest filing, from $4.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $43.8 million in Q1 2022 and bottomed at $1.1 million in Q1 2024.
- Historically, Cash & Current Investments has averaged $12.4 million across 5 years, with a median of $6.6 million in 2025.
- Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 86.79% — and 2025, when it soared 522.12%.
- Matinas BioPharma Holdings' Cash & Current Investments stood at $6.9 million in 2022, then declined by 29.69% to $4.8 million in 2023, then jumped by 51.62% to $7.3 million in 2024, then slumped by 44.79% to $4.0 million in 2025, then tumbled by 39.54% to $2.4 million in 2026.
- Business Quant data shows MTNB's Cash & Current Investments at $2.4 million in Q1 2026, $4.0 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | 811,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 811,000.00 |
| Mar 31, 2026 | 2.45 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Sep 30, 2025 | 5.49 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 7.33 Mn |
| Sep 30, 2024 | 10.35 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 4.84 Mn |
| Sep 30, 2023 | 6.46 Mn |
| Jun 30, 2023 | 22.51 Mn |
| Mar 31, 2023 | 5.79 Mn |
| Dec 31, 2022 | 6.88 Mn |
| Sep 30, 2022 | 33.05 Mn |
| Jun 30, 2022 | 38.50 Mn |
| Mar 31, 2022 | 43.83 Mn |
| Dec 31, 2021 | 49.62 Mn |
| Sep 30, 2021 | 53.82 Mn |